Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
NCT00501293
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
163
Enrollment
INDUSTRY
Sponsor class
Conditions
ADHD
Interventions
DRUG:
Methylphenidate Transdermal System
Sponsor
Noven Therapeutics